Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease.
Cardiovascular disease is the leading cause of death worldwide, with high medical costs and rates of disability. It is therefore important to evaluate the use of cardiovascular biomarkers in the early diagnosis of coronary artery disease (CAD). We have screened a variety of recently identified bioactive peptides candidates in anticipation that they would allow detection of atherosclerotic CAD. Especially, we have focused on novel anti-atherogenic peptides as indicators and negative risk factors for CAD. In vitro, in vivo and clinical studies indicated that human adiponectin, heregulin-β(1), glucagon-like peptide-1 (GLP-1), and salusin-α, peptides of 244, 71, 30, and 28 amino acids, respectively, attenuate the development and progression of atherosclerotic lesions by suppressing macrophage foam cell formation via down-regulation of acyl-coenzyme A: cholesterol acyltransferase-1. Circulating levels of these peptides in the blood are significantly decreased in patients with CAD compared to patients without CAD. Receiver operating characteristic analyses showed that salusin-α is a more useful biomarker, with better sensitivity and specificity, compared with the others for detecting CAD. Therefore, salusin-α, heregulin-β(1), adiponectin, and/or GLP-1, alone or in various combinations, may be useful as biomarkers for atherosclerotic CAD.
Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. watanabe@toyaku.ac.jp
Takuya
T
Watanabe
Kengo
K
Sato
Fumiko
F
Itoh
Kohei
K
Wakabayashi
Masayoshi
M
Shichiri
Tsutomu
T
Hirano
D050197:Atherosclerosis / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism*; D003327:Coronary Disease / Q000378:metabolism*; D006801:Humans; D010455:Peptides / Q000378:metabolism*
D015415:Biomarkers; D010455:Peptides